Gene editing technology developer Metagenomi advances research from UC Berkeley and has raised a series A co-led by Bayer.

Metagenomi, a US-based gene editing technology spinout of University of California (UC), Berkeley, has raised $64m in a series A round co-led by pharmaceutical and agricultural product maker Bayer. Humboldt Fund co-led the round, which also featured Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital. Bayer invested through corporate venturing subsidiary Leaps by Bayer.…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.